Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.
BACKGROUND Paediatric antiretroviral fixed-dose combination tablets remain limited. UNIVERSAL1 evaluated pharmacokinetics, short-term safety, and antiviral activity of novel fixed-dose ratios of dolutegravir, emtricitabine, and tenofovir alafenamide in children with HIV. METHODS UNIVERSAL1 was an open-label, single-a...